Polycythemia vera: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Aleksander Stos
(cleanup)
imported>Subpagination Bot
m (Add {{subpages}} and remove any categories (details))
Line 1: Line 1:
{{subpages}}
== Clinical criteria ==
== Clinical criteria ==


Line 8: Line 10:
==References==
==References==
<references/>
<references/>
[[Category: Health Sciences Workgroup]]
[[Category: CZ Live]]

Revision as of 10:31, 13 November 2007

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Clinical criteria

JAK2 mutations

Mutations in the JAK2 gene, specifically at the V617F locus, give rise to myeloproliferative disorders such as essential thrombocythemia and polycythemia vera.[1]

Authors reported[2] that other mutations of the coding region of the JAK2 gene could create a polycythemia phenotype.

References

  1. Scott, et al. New Engl J Med 356: 459-468 2007.
  2. James, et al. Nature 434:1144-8 2005.